By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
DenyAccept
Press Release
CEO Dr Katerina Spranger awarded the Princess Royal Silver Medal by the Academy of Engineering
Read more
In The Press
AI-driven technology could transform aneurysm treatment
Read more
Press Release
PreSize® trial receives ethics and compliance approval
Read more
Press Release
Oxford Heartbeat secures highly sought-after Innovate UK award
Read more
In The Press
The Telegraph: From Musk to Bezos: the remarkable rise of the executive engineer
Read more
Press Release
PreSize® Neurovascular is launched in the NHS
Read more
Press Release
Interview with Enterprising Oxford
Read more
Press Release
July 9, 2025

PreSize® Neurovascular Landmark Clinical Impact Trial Receives ESMINT Endorsement

The clinical impact trial of Oxford Heartbeat's decision-support software, PreSize® Neurovascular, has been endorsed by The European Society of Minimally Invasive Neurological Therapy (ESMINT).
Press Release
November 15, 2024

CEO Dr Katerina Spranger Receives Purple Plaque Honour from Innovate UK

Dr Katerina Spranger has been honoured with a Purple Plaque in recognition of winning the prestigious Innovate UK Women in Innovation Award
Press Release
September 12, 2024

Recruitment Complete for Landmark Clinical Impact Trial of PreSize® Neurovascular

The clinical trial collecting evidence on the impact of PreSize® Neurovascular has successfully recruited all 100 patients…
Press Release
July 9, 2024

CEO Dr Katerina Spranger awarded the Princess Royal Silver Medal by the Academy of Engineering

Dr Spranger received the prestigious Princess Royal Silver Medal from the Royal Academy of Engineering, in recognition of an outstanding personal contribution to UK engineering.
Press Release
December 20, 2023

Halfway Point Reached in Clinical Impact Trial of PreSize® Neurovascular

The clinical trial collecting evidence on the impact of PreSize® Neurovascular in a clinical setting has reached the halfway point for recruitment…
Jan 20, 2022

PreSize® trial receives ethics and compliance approval

Oxford Heartbeat secures ethics and HRA approval to commence clinical trials...

Get in touch to find out more about PreSize®

Contact us
Technology
Company
Insights
Privacy Policy
Terms & Conditions
©2025 Oxford Heartbeat®. All rights reserved.
Shaping the surgery of tomorrow
Shaping the surgery of tomorrow